Navigation Links
Research Solutions Launches New Software-as-a-Service Compliance Solution for Pharmaceutical Companies
Date:5/14/2013

pan>, Head of Global Services at Reprints Desk. "While paper reprints are still a valuable leave-behind during an HCP detail or at professional meetings, transitioning to ePrints can make it easier to comply with new industry regulations and Research Solutions' subsidiary Reprints Desk is the company that can help."

Scholarly, peer-reviewed journal articles are important educational tools for healthcare professionals, helping them to understand new therapies and stay current on changing standards of care. Reprints Desk improves how journal articles and clinical reprints are accessed, procured, and legally used in evidence-based promotions and scientific, technical, and medical (STM) research. In June 2012, Reprints Desk launched the content-enriched website www.hcpengage.com, featuring video interviews with healthcare professionals and industry thought leaders on topics such as regulatory compliance, sales rep interactions, scientific literature usage, mobile usage and more.

For more information, please contact Ian Palmer at +1 (415) 533-8308.  Additional information can also be found online at www.researchsolutions.com.

About Research Solutions, Inc.
Research Solutions (formerly Derycz Scientific, Inc.) and its wholly-owned subsidiary Reprints Desk (www.reprintsdesk.com) deliver research information services and software to research-intensive organizations in Life Sciences and other industries.

Forward-Looking Statements
Certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive facto
'/>"/>

SOURCE Research Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
2. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
3. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
4. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
5. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
6. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
7. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
8. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report
11. Okuma America Chooses The Daniel Group To Provide Customer Service Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, announced the start of a phase 1 ... will explore the safety, pharmacokinetics,pharmacodynamics and anti-tumor activity ... MT110 targets the epithelial cell adhesion molecule ...
... an oncolytic product, WOBURN, Mass., April 22 ... treatments for cancer and the prevention,of infectious disease, ... (FDA) has approved the design of a single, ... OncoVEX(GM-CSF) in,previously treated patients with metastatic melanoma. The ...
Cached Medicine Technology:Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 2Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 3Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 4Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 5BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 2BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 3
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... 2014 (HealthDay News) -- The risk of burns from ... you need to be extra cautious, an expert says. ... a significant increase in patients coming in with burns," ... County Volunteer Firefighters Burn Center of Stony Brook University ... full of joy, but if not careful, could quickly ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... Calif., March 20 Poniard Pharmaceuticals, Inc. (Nasdaq: ... on oncology, today announced that it will concentrate ... development of its late-stage oncology candidate, picoplatin. As ... preclinical research operations and reduced its workforce by ...
... Qutenza(TM) Receives Positive Committee Recommendation in European ... approval of Qutenza(TM) (formerly NGX-4010) for treatment ... either alone or in combination with other ... for review by U.S. FDA for PHNUpcoming ...
... March 20 Nuvilex, Inc. (OTC Bulletin Board: NVLX), formerly ... for the live conference call held on March 19, 2009 ... March 19, 2009 at 7:30 PM ET to March 26, ... 1-877-660-6853 (U.S.) and 1-201-612-7415 (international). To listen to the ...
... A campaign which will reduce mortality in patients with ... coalition which includes the ESC Working Group on Acute ... Interventions (EAPCI). "Stent 4 Life" is a project designed ... percutaneous coronary interventions (PCI, with balloon angioplasty and stent) ...
... leading private equity investment fund ("JLL"), and PharmaNet Development ... (Nasdaq: PDGI ) ("PharmaNet"), today announced the ... Holdings, LLC ("Parent"), through its wholly-owned subsidiary, PDGI Acquisition ... common stock of PharmaNet. Parent and Purchaser are ...
... to work, maybe you can walk at work ... 3 is National Walk to Work Day. ... Human Services, the sixth-annual event encourages Americans to ... http://www.newscom.com/cgi-bin/prnh/20090320/DE86407 )The reason is clear: According to ...
Cached Medicine News:Health News:Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization 2Health News:Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 8Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 9Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 10Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 11Health News:Nuvilex Provides Conference Call Replay Information 2Health News:'Stent 4 Life': A campaign is launched to increase the use of primary PCI in acute coronary patients 2Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 2Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 3Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 4Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 5Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 6Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 7Health News:National Walk to Work Day is April 3 2Health News:National Walk to Work Day is April 3 3
CVC 223 is an assayed quality control material used for confirming the calibration and linearity of CO-Oximeter instrumentation....
... control material used for monitoring the performance of ... for specific use on Bayer analyzers that measure ... 270) and the AVOX Systems CO-Oximeters (4000 and ... the IRMA TRUpoint. CC 527 is available in ...
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
... is a reagent and probe system used ... high throughput plate based system is a ... a unique approach for RNA detection and ... branched DNA (bDNA) technology. Branched DNA allows ...
Medicine Products: